Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  6.50 1.96% 338.00 46,230 15:17:48
Bid Price Offer Price High Price Low Price Open Price
336.00 340.00 338.00 331.50 331.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 72.11 5.21 3.82 88.5 228
Last Trade Time Trade Type Trade Size Trade Price Currency
17:10:00 O 1,500 338.00 GBX

Eco Animal Health (EAH) Latest News (1)

More Eco Animal Health News
Eco Animal Health Investors    Eco Animal Health Takeover Rumours

Eco Animal Health (EAH) Discussions and Chat

Eco Animal Health Forums and Chat

Date Time Title Posts
04/3/202115:09Eco Animal Health Group: Early dewormer gets OK1,205

Add a New Thread

Eco Animal Health (EAH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eco Animal Health trades in real-time

Eco Animal Health (EAH) Top Chat Posts

Eco Animal Health Daily Update: Eco Animal Health Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EAH. The last closing price for Eco Animal Health was 331.50p.
Eco Animal Health Group Plc has a 4 week average price of 282.50p and a 12 week average price of 227.50p.
The 1 year high share price is 345p while the 1 year low share price is currently 125p.
There are currently 67,517,126 shares in issue and the average daily traded volume is 83,578 shares. The market capitalisation of Eco Animal Health Group Plc is £228,207,885.88.
cerrito: I have been going through both the recently published AR and the interims to see if I should increase my holding. I think I will stay where I am for now but would appreciate comments from you all as to where I have misunderstood. One big reason for me not buying more is I am having difficulty in understanding the company and one reason for that is that they do not appear to bother with IR for their retail investors. I take the point that it appears unlikely that they will need to do a fund raise in the immediate future and that those holding over 3% have a combined 65% share holding-ie retail investors are less important than in some other companies. That said they could have been more welcoming in their AGM like for example CWR and ITM or at the very least have done an Investor Meets Company type operation. I should add that the Finances seem better managed than in the past. It was surprising to read n page 126 of the AR that over an extended period an ex Director had helped herself to £300k+ without it being picked by internal or external auditors. Also, a bit disorientating to see that in the two years to March 2020 they paid out £18m in dividends and then we read in the latest interims they had to cut back on their R&D programme as they had insufficient cash. Suggests that perhaps a,lack, in the past, of long term strategic financial planning. What is welcome that there is now more transparency as to where the cash is i.e., China or non China than we seem to have had in the past. It is of course great that consolidated net cash grew from £9.8m at end March 2020 to £12.9m at end September 2020. However, that was due to cash balances of the Chinese company growing from £5.3m to £9.7m and cash balances ex China decreasing from £4.5m to £3.2m. The interims recognize that this cash balance in China-51% owned by EAH- gets transferred by dividends, as one would expect. It would be interesting to know when the next dividend will be paid. My reading of Pages 105/7 of the AR is that EAH would have got £1.6m and £0.97m in FY 2018/19 and 19/20 respectively…but please check that. Let’s hope that this next dividend is going to be higher. My reading of page 106 of the AR which shows a decline in 2020 over 2019 in plant and equipment of the Chinese JV is that the new factory in China is not owned by the JV but rather one assumes by a 100% owned EAH company…is that how you understand it? Begs the question to me is how they realize their factory investment in pounds sterling. All in all, I can well understand why they are not paying a dividend and I go on the basis that any dividend for this FY will be token. I note that the overdraft facility reported on Page 115 of the AR was new. I admit I am surprised that this facility repayable on demand is secured with what would appear to be a highish margin of 1.8%. All seems rather odd to me and suggests that the bank not all that comfortable. Page 116 tells us that the weighted average incremental borrowing rate for lease finance is a, to me, high 7.1%, I was interested to read page 87 of the AR with its good table of in which geographic markets they make their Ebitda. Interesting to see that in the year to 3/20 S and SE Asia far more profitable than China and Japan as regards adjusted ebitda to revenue from external customers and total assets but guess the picture will be different this FY
ifaze: I suspect that the pull back in share price is due to short term punters buying in anticipation of the results, who wanted/needed to sell rather than wait for January (or later). I'm long term.
cerrito: The fact that they will need 8 months + to prepare their accounts even with Covid is pretty poor and gives a bad impression. I cannot recall any other company I have shares in needing such a long delay. No idea how much the new auditor BDO is to blame. Perhaps we will get the September interims before the March finals. Once again they talk about market expectations without specifying what they understand these to be. My reading is that for the current FY the forecast is 9.54p eps up from the forecast of 7.8p for the last FY, but well down from that for 2017,18 and 19, Do any of you have an understanding of this?? I assume these come from N+! Singer and Friedlander and perhaps Peel Hunt. AFS would appear to be less of an issue. See hxxps:// Incidentally, I transcribe something I posted on the ANP site yesterday which is also relevant to EAH. Quote Thought on ANP this morning when I read a piece in the FT of the formation of Investor Action on Antimicrobial Resistance which is backed by institutional investors with U$7tn under management to reduce use of antibiotics everywhere including food production. hxxps:// While the immediate impact on the ANP bottom line will I assume be muted, it all helps. unquote
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days ago and part of our discussion includes EAH. We also chatted about loads of other Stocks and Ideas for research, and the outlook for Markets and as usual a fair bit of educational stuff with regards to Investing which this week included the concept of ‘Badwill’ and a lot on how we seek out ‘under the radar’ stocks. Anyway, if you use Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 34) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, Cheers, WD @wheeliedealer hTTps://
hatfullofsky: A current year trading update will be provided after the half year ending on 30 September 2020.Come on EAH get a wiggle on !
1aconic: Yeah, the websites are awful! I just assume that most selling is through distribution channels and not so much ad hoc direct customer chasing - from what I can gather that's the case with a lot of vetinary medicines but not entirely sure over everything EAH does. There was another big round of selling (an almost identical 725,000 equating to over 1%) in late Sept. My thinking on that is one of the institutions is reducing because of the Germany ASF outbreak. Think it might be just part on an institution being cautious and don't want to be caught by a major problem they have to explain to investment boards and fund holders. They'd rather sell now and buy later at a much higher price when it's de-risked (e.g. a vaccine announced) a bit rather than be caught with their pants down. I personally think it's a little short sighted as EAH seems to be holding up well in terms of revenue despite it's main market already having been absolutely decimated. Would be interested to hear other people's views on that too.
1aconic: Took another long look here this week. Definitely still some risks - the latest outbreak of ASF in Germany illustrates that and the US/China trade tensions are still a background concern. But there are plenty of postives too: a potential ASF vaccine reported not long ago; from the trading update EAH's own revenues will be above last year thanks to improved margins and taking competitor market share(unless I'm missing something that's a pretty impressive performance under the conditions?); new reports this week that China has almost exhausted its frozen pork stockpiles and prices are soaring; EAH potentially has some new developments coming out of the R&D dept on which specific updates may not be too far away; etc, etc. I personally think there's still plenty to be positive about in the medium term and calculate that the risk has been priced in far more than the potential. I've doubled up my holding after the price pulled back a bit this week. GLA.
cerrito: Thought of EAH this morning reading a story in the FT on the food situation. Pork prices up 86% in July compared to a year earlier which would be good news for EAH. Not so good news was major flooding in Sichuan province-China's top pork producer.
cerrito: Re the Friday RNS, given that the EMA has signed off on these for poultry products, I have no idea how significant it is what the EMA are doing with pork; that said good news. Over recent weeks has been pretty quiet on the ASF front, except that it has got to India where EAH do not appear to have much activity. Perhaps reflects the world cannot focus on both Covid and ASF. No idea if EAH working on a vaccine for ASF or even if one is feasible. However would have thought this was for a company with deeper pockets than EAH, Went onto the corporate and commercial website to see if there was any news, but just silence.
cerrito: I can understand why you did what you did Mach100, although my reading of the latest news items is that Japan does not have ASF but does have classical swine virus. That said I am not buying more and if it does make its way to the Americas I hesitate to think what will happen to the share price. Still perplexed that ANP share price is unmoved by all of this.
Eco Animal Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210304 23:13:36